Table 2.

Overall Survival Subsequent to Brain Metastases

Characteristics	Median, mo	1-Year Survival	Lower 95% CI	Upper 95% CI	P
Overall survival	6	30%	23%	36%	–
HER-2
Negative	5	17%	11%	25%
Positive	9	45%	35%	54%	.002
Subtypes					.0069
Hormone positive/HER-2 negative	5	23%	14%	35%
HER-2 positive	9	45%	35%	54%
Triple receptor negative	5	29%	17%	42%
Age, y
<50	8	34%	25%	43%
≥50	5	25%	17%	34%	.078
Race
White	8	30%	23%	38%
Black	3.5	17%	7.4%	31%
Other	6	40%	24%	56%	.007
Stage of disease
I/II/III	8	47%	32%	61%
IV	6	30%	23%	37%	.049
No. of positive lymph nodes
<10	6	29%	22%	37%
>10	4	21%	5.8%	42%	.045
Grade of primary breast tumor
1/2	8	32%	17%	49%
3	6	30%	22%	37%	.722
Lymphovascular invasion of primary breast tumor
No	6	31%	22%	40%
Yes	6	28%	18%	39%	.563
Site of first metastases
Visceral only	4	21%	12%	32%
Bone only	6	31%	13%	50%
Brain only	9	40%	22%	72%
Multiple	9	40%	28%	50%
Other	6	16%	5.5%	31%	.0705
No. of brain metastases
<3	8	34%	22%	46%
≥3	6	28%	21%	36%	.064
WBRT
Alone	5	24%	18%	31%
Plus surgery or radiosurgery	14	53%	35%	67%	<.0001
Radiation dose, Gy
<30	1	–	–	–
≥30	7	31%	25%	38%	<.0001
RPA class
I/II	11	45%	36%	54%
III	2	6%	20%	14%	<.0001
KPS
<70	2	16%	19.1%	25%
≥70	11	45%	36%	53%	<.0001
Extracranial metastases
No	9	50%	19%	74%
Yes	6	28%	22%	35%	.117

CI indicates confidence interval; WBRT, whole brain radiotherapy; Gy, grays; RPA, recursive partitioning analysis; KPS, Karnofsky performance status.